<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256399</url>
  </required_header>
  <id_info>
    <org_study_id>L-9835</org_study_id>
    <nct_id>NCT00256399</nct_id>
  </id_info>
  <brief_title>Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)</brief_title>
  <official_title>A Prospective, Open Label, Study to Assess the Efficacy of Alfuzosin 10 mg Tablet Once a Day in Male Subjects Suffering From Benign Prostate Hypertrophy Associated Lower Urinary Tract Symptoms and Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <brief_summary>
    <textblock>
      Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in
      males with BPH and ED.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a 30 day screening/washout phase at the end of which qualified
      subjects will be assigned to alfuzosin 10 mg tablets once a day. Subjects will be treated for
      90 days. The total duration of the study will be 120 days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the medication on erection maintenance</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess effect of Uroxatral on BPH and sexual function using questionnaires</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>BPH</condition>
  <condition>Erectile Dysfunction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin 10 mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 45-75 years of age

          -  Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED

          -  Men with steady partner and who agree to attempt sex once a week.

        Exclusion Criteria:

          -  Prostate cancer

          -  Prostatitis

          -  Penile disease

          -  Cardiac co-morbidity

          -  Pre-existing co-morbid conditions

          -  History of sensitivity to the drug or similar drugs

          -  Enrollment in another clinical trial

          -  Impaired hepatic function

          -  Impaired renal function

          -  Mental conditions rendering subject unable to understand the study

          -  Subjects not likely to comply with protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen D Seftel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Urologists of Cleveland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann M Serenko, MS, RN</last_name>
      <phone>216-844-3515</phone>
      <email>ann.serenko@uhhs.com</email>
    </contact>
    <contact_backup>
      <last_name>Allen D Seftel, MD</last_name>
      <phone>216-844-7728</phone>
      <email>adseftel@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allen D Seftel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Resnick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald Bodner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

